The next generation of weight loss drugs will hit the market in 2026. Eli Lilly and Novo Nordisk are racing to the finish ...
Novo's upcoming Alzheimer's trial results will test whether Rybelsus can slow cognitive decline and reshape treatment ...
GLP-1 RAs, particularly semaglutide and tirzepatide, outperform older medications in achieving significant weight loss in adults with and without type 2 diabetes. Semaglutide and tirzepatide met ...
Biotech companies are racing to find Ozempic 2.0, hoping for a slice of a multi-billion-dollar industry. A few stand-out ...
Public News Service on MSN
MS Medicaid patients face hurdles to getting weight loss drugs
By Phil Galewitz for KFF Health News. Broadcast version by Trimmel Gomes for Mississippi News Connection reporting for the ...
Rybelsus is a Food and Drug Administration (FDA)-approved medication for treating type 2 diabetes. Like Ozempic and Wegovy, it contains the active ingredient semaglutide. This is a type of GLP-1 ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback